登录并加购,请在购物车里查看协议价、货期和发货地。
选择规格
变更视图
关于此项目
经验公式(希尔记法):
C25H34O6
化学文摘社编号:
分子量:
430.53
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
257-139-7
MDL number:
Assay:
≥99%
Form:
powder
产品名称
布地奈德, ≥99%
Quality Segment
assay
≥99%
form
powder
originator
AstraZeneca
SMILES string
[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])C[C@H]5OC(CCC)O[C@@]45C(=O)CO
InChI
1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1
InChI key
VOVIALXJUBGFJZ-KWVAZRHASA-N
Gene Information
human ... IFNG(3458), IL5(3567), NR3C1(2908)
rat ... Nr3c1(24413)
Biochem/physiol Actions
Budesonide is a second generation glucocorticoid with low systemic absorption. It is used as an anti-inflammatory agent in the treatment of asthma, rhinitis, and inflammatory bowel disease. It inhibits the expression of chemokine mRNA and production of eotaxin and RANTES protein in primary human bronchial epithelial cells. Budesonide is currently in clinical trials for the prevention of lung cancer. It shows inhibitory effects on benzo[a]pyrene-induced carcinogenesis of the lung in mice.
Second generation glucocorticoid with low systemic absorption; anti-inflammatory agent; inhibits the expression of chemokine mRNA and production of eotaxin and RANTES protein.
Features and Benefits
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Still not finding the right product?
Explore all of our products under 布地奈德
signalword
Danger
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Chronic 3 - Repr. 2 - Skin Sens. 1 - STOT RE 1 Inhalation
target_organs
Adrenal gland
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)

